Table 3.
Analytical parameters for the SPE-LC-MS/MS and SPE-UHPLC-MS/MS methods
| Nº | Compound | RSDa(%) n=6 | LODb(ng/L) | LOQc(ng/L) | Recovery (%) n=6 |
|---|---|---|---|---|---|
| 1 | Naproxen | 9.6 | 0.6 | 1.8 | 101.8 ± 7.0 |
| 2 | Carbamazepine | 10.7 | 0.3 | 1.1 | 105.6 ± 4.4 |
| 3 | Ketoprofen | 9.2 | 2.4 | 7.9 | 98.6 ± 9.4 |
| 4 | Bezafibrate | 7.8 | 2.9 | 9.6 | 91.6 ± 11.4 |
| 5 | Atenolol | 6.5 | 7.9 | 26.3 | 67.2 ± 4.4 |
| 6 | Metamizole | 7.9 | 6.3 | 21.1 | 54.4 ± 4.3 |
| 7 | Paraxanthine | 10.8 | 2.2 | 7.8 | 96.4 ± 10.4 |
| 8 | Fluoxetine | 7.7 | 97.4 | 324.7 | 21.0 ± 1.6 |
| 9 | Levofloxacin | 8.5 | 9.1 | 30.3 | 82.4 ± 14.0 |
| 10 | Norfloxacin | 8.5 | 8.5 | 28.0 | 85.3 ± 5.2 |
| 11 | Ciprofloxacin | 6.8 | 8.6 | 28.7 | 86.2 ± 2.1 |
| 12 | Enrofloxacin | 7.0 | 5.3 | 17.7 | 94.0 ± 6.1 |
| 13 | Sarafloxacin | 9.8 | 11.1 | 37.0 | 86.1 ± 11.2 |
aRelative Standard Derivation.
bDetection limits, calculated as signal to noise ratio of three times.
cQuantification limits, calculated as signal to noise ratio of ten times.